View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
LAC. LITHIUM AMERICAS CORP NEW
ORKA ORUKA THERAPEUTICS INC
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

HealthEquity Strengthens Executive Leadership Team with Strategic Appo...

HealthEquity Strengthens Executive Leadership Team with Strategic Appointments to Drive Growth and Innovation New CMO and Sales Executive Join from Mastercard and EverQuote to Capitalize on Historic HSA Market Expansion DRAPER, Utah, Sept. 25, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HQY), the nation’s largest Health Savings Accounts (HSAs) and consumer-directed benefits administrator, today announced the appointment of new senior executives to accelerate the company's strategic vision and capitalize on expanding market opportunities. joins as Chief Marketing Officer and as Senior Vic...

Healthequity Inc: 1 director

A director at Healthequity Inc sold 6,000 shares at 94.108USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Moody's Ratings affirms the Baa2 senior unsecured rating of Marriott I...

Moody's Ratings (Moody's) affirmed its ratings assigned to Marriott International, Inc. (Marriott), including the Baa2 senior unsecured rating and the P-2 commercial paper program rating. We also affirmed the Baa2 senior unsecured rating for Starwood Hotels & Resorts Worldwide Inc. (Starwood). The r...

 PRESS RELEASE

HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Resu...

HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results Highlights of the second quarter include: Revenue of $325.8 million, an increase of 9% compared to $299.9 million in Q2 FY25.Net income of $59.9 million, an increase of 67% compared to $35.8 million in Q2 FY25, with non-GAAP net income of $94.6 million, an increase of 24% compared to $76.3 million in Q2 FY25.Net income per diluted share of $0.68, an increase of 70% compared to $0.40 in Q2 FY25, with non-GAAP net income per diluted share of $1.08, an increase of 26% compared to $0.86 in Q2 FY25.Adjusted EBITDA of $1...

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

HealthEquity's AI-Powered Tool Recognized for Innovation in Streamlini...

HealthEquity's AI-Powered Tool Recognized for Innovation in Streamlining Benefits Education Industry Leader’s HSAnswers Wins Multiple Awards to Transform Complex Healthcare Benefits Information to Accessible and Reliable Intel For Millions DRAPER, Utah, Aug. 29, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: HQY), the nation’s largest Health Savings Accounts (HSAs) and consumer-directed benefits administrator, today announced that its innovative AI-powered educational tool, , has received multiple prestigious industry awards recognizing its excellence in artificial intelligence and benefits e...

 PRESS RELEASE

CORRECTION - HealthEquity Community Foundation Expands National Impact...

CORRECTION - HealthEquity Community Foundation Expands National Impact with $50,000 in Grants Funding supports 20 nonprofit organizations focused on physical and mental health, financial literacy, and basic needs as the foundation grows and welcomes a new leader DRAPER, Utah, Aug. 12, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by HealthEquity, Inc., please note that the list of organizations that received funding in the summer 2025 grant cycle has been updated. The corrected release follows: The today announced its latest round of grant recipi...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch